Comparative structural and biochemical analyses of full-length ASXL1 and truncated cancer-associated ASXL1 mutations could shed light on their functional consequences and the molecular mechanisms underlying ASXL1 mutations in MDS and AML. The gene discussed is ASXL1; the disease is cancer.